Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks

Raya Ortega L, Marquez Calderon S, Navarro Caballero J A, Villegas Portero R
Record ID 32006000205
Spanish
Authors' objectives: The aim of this report is to determine whether the use of palivizumab is cost-effective in preventing hospitalisation and morbi-mortality due to syncytial respiratory virus (SRV) infection in premature infants born at 32 to 35 weeks gestational age.
Authors' results and conclusions: Of the 416 articles retrieved in the search, only two meeting the inclusion criteria were selected, namely, a controlled clinical trial and a cohort study, both with sound internal validity. Only one of the studies records the number of deaths, although these were unrelated to palivizumab. Both studies measure the frequency of hospitalisation and length of stay for SRV-induced respiratory infection, although only the cohort study provides data on absolute risk reduction specifically for the premature population born at 32 to 25 weeks. According to this study, the absolute risk reduction for SRV-induced hospitalisation is 3.9% (2.7 Intervention group vs. 6.6 % control group).
Authors' recommendations: In the population of 32- to 35-week gestational age infants, palivizumab is effective as prophylaxis for SRV infection, but it is not cost-effective.
Authors' methods: Review
Details
Project Status: Completed
URL for project: https://www.aetsa.org/publicacion/coste-efectividad-de-palivizumab-en-le-prevencion-de-la-hospitalizacion-por-virus-respiratorio-sincitial-en-prematuros-de-32-a-35-semanas-de-gestacion/
Year Published: 2006
URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/2014_AETSA_Palivizumab_.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Antibodies, Monoclonal
  • Antiviral Agents
  • Costs and Cost Analysis
  • Infant, Premature
  • Respiratory Syncytial Viruses
  • Respiratory Syncytial Virus Infections
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.